A dependency of the prognostic impact of a certain biomarker on the received treatment has also been described in other diseases, e.g., the impact of the BCR-ABL translocation in acute lymphoblastic leukemia (ALL) treated with kinase inhibitors [103] and especially the Burkit B cell variant of ALL that was originally regarded as a high-risk variant but was later classified as a favorable variant when new therapeutic strategies were introduced [104]. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.